



Children's Community Health Plan (CCHP) recognizes that some of its members are prescribed antipsychotic medications. Though these medications can play an important role for patients, both first-generation (typical) and second-generation (atypical) antipsychotics can put patients at risk for side effects such as weight gain, dyslipidemia, and impaired glucose control which can contribute to the development of diabetes mellitus and cardiovascular disease. Monitoring for side effects is important in patients prescribed these medications, especially children and adolescents who are more susceptible to developing adverse effects.

If you prescribe one or more of the following medications...

Antipsychotic Medications

Description		Prescription	
Miscellaneous antipsychotic agents	Aripiprazole Asenapine Brexpiprazole Cariprazine Clozapine Haloperidol	Iloperidone Loxapine Lurisadone Molindone Olanzapine Paliperidone	Pimozide Quetiapine Quetiapine fumarate Risperidone Ziprasidone
Phenothiazine antipsychotics	Chlorpromazine Fluphenazine Perphenazine	Thioridazine Trifluoperazine	
Thioxanthenes	Thiothixene		
Long-acting injections	Aripiprazole Fluphenazine decanoate Haloperidol decanoate	Olanzapine Paliperidone palmitate Risperidone	

Antipsychotic Combination Medications

Description	Prescription	
Psychotherapeutic combinations	Fluoxetine-olanzapine	Perphenazine-amitriptyline

Prochlorperazine Medications

Description	Prescription
Phenothiazine antipsychotics	Prochlorperazine

Clinical gu the follow

Clinical guidelines¹ recommend ordering the following metabolic laboratory tests.

Blood Glucose Level OR Hemoglobin A1c

AND

LDL-C Level OR Cholesterol Level

*These labs may be either fasting OR non-fasting

¹Practice Parameter for the Use of Atypical Antipsychotic Medications in Children & Adolescents (2011).

Published by the American Academy of Child & Adolescent Psychiatry

Clinical Guidelines¹ recommend performing metabolic laboratory tests on the following schedule:

At baseline (before starting initial medication therapy)

Every 12 months thereafter

3 months after starting medication therapy

CCHP is proud to partner with all our network providers and our members!

If you have any questions about these clinical guideline recommendations, please contact CCHP's Clinical Quality Improvement Department at 414-266-3268.

The Wisconsin Child Psychiatry Consultation Program (CPCP) can provide practitioners consultation and support in managing patients with mental and behavioral health conditions: visit www.chw/cpcp for more information.